The Bioscan AN INTERNATIONAL QUARTERLY JOURNAL OF LIFE SCIENCES 20(3): S.I (3), 486-490, 2025 www.thebioscan.com

FUNGAL COINFECTIONS IN COVID-19 PATIENTS: A COMPREHENSIVE REVIEW OF MUCORMYCOSIS, ASPERGILLOSIS, AND CANDIDA AURIS

Geetha C [*1], Kiran kumar S [2], Sowmiya B[3], Nirmala B [4]and Durai murugan S[5]

[1]Department of Nursing, PERI College of Nursing, Chennai -48

[2]Department of Physiotherapy, PERI College of Physiotherapy, Chennai -48

[3]Department of Pharmacy, PERI College of Pharmacy, Chennai -48

[4]Department of Microbiology, PERI College of Arts and Science, Chennai – 48

[5]Department of Computer Science and Engineering, PERI Institute of Technology, Chennai - 48

Corresponding mail id: publications@peri.ac.in

DOI: 10.63001/tbs.2025.v20.i03.S.I(3).pp486-490

KEYWORDS
COVID-19; fungal coinfections; mucormycosis; Candida auris; pulmonary aspergillosis; antifungal therapy; corticosteroids; diabetes mellitus; pharmacological management; opportunistic infections

Received on:

16-06-2025

Accepted on:

12-07-2025

Published on:

20-08-2025

ABSTRACT

The emergence of fungal coinfections in patients with COVID-19 has introduced a new dimension of clinical complexity, particularly in individuals with underlying immunosuppression or comorbidities such as diabetes mellitus. Opportunistic fungal pathogens, including *Mucorales* (mucormycosis), *Aspergillus spp.* (COVID-19-associated pulmonary aspergillosis, CAPA), and *Candida auris*, have shown an alarming rise during the pandemic, often mimicking or compounding COVID-19 respiratory symptoms. These infections are associated with high morbidity and mortality, especially when diagnosis and intervention are delayed. This review highlights the pharmacological aspects of managing fungal infections in COVID-19 patients, emphasizing the challenges in antifungal therapy, drug resistance, and immunomodulatory treatment strategies. Corticosteroid therapy, a cornerstone in severe COVID-19 treatment, has paradoxically increased susceptibility to fungal invasion by impairing host immune responses and elevating blood glucose levels. Mucormycosis, in particular, has seen a dramatic surge in India during the second wave of COVID-19, necessitating aggressive surgical and pharmacological intervention with liposomal amphotericin B, posaconazole, or isavuconazole. Preventive pharmacological measures, such as glycemic control, judicious steroid use, and sterilization of oxygen humidifiers, are crucial to reduce the incidence of these secondary infections. Enhanced diagnostic protocols, antifungal stewardship, and ongoing clinical trials on novel therapeutics are essential for improving patient outcomes. This comprehensive review serves to inform clinicians, pharmacists, and researchers of the evolving fungal landscape in the COVID-19 era and offers pharmacological insights into evidence-based management strategies for these life-threatening coinfections.

INTRODUCTION

The global COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has posed unprecedented challenges to healthcare systems worldwide. While the primary focus has been on controlling viral transmission and managing acute respiratory illness, increasing evidence points to a secondary, yet severe, threat: opportunistic fungal infections. These coinfections, including mucormycosis (commonly known as "black fungus"), COVID-19-associated pulmonary aspergillosis (CAPA), and *Candida auris*, have emerged with alarming frequency in COVID-19 patients, particularly those with underlying immunosuppressive conditions or comorbidities such as diabetes mellitus. Fungal coinfections complicate the clinical course of COVID-19, often mimicking or exacerbating respiratory symptoms, which leads to diagnostic delays and worsened prognosis. The widespread and sometimes indiscriminate use of corticosteroids and broad-spectrum antibiotics—critical in managing severe COVID-19 cases—has inadvertently contributed to an environment conducive to fungal proliferation. Notably, India witnessed a surge in mucormycosis cases during the second wave of the pandemic, largely affecting post-COVID-19 diabetic patients treated with steroids and supplemental oxygen therapy. From a pharmaceutical standpoint, managing these coinfections presents numerous challenges. The choice of antifungal agents, concerns about nephrotoxicity (e.g., with amphotericin B), drug-drug interactions, and the emergence of antifungal resistance necessitate a cautious and informed therapeutic approach. Furthermore, the scarcity of antifungal drugs, especially in low-resource settings, adds another layer of complexity to treatment protocols. This review aims to provide a comprehensive overview of the pathogenesis, clinical presentation, diagnostic considerations, and pharmacological management of fungal infections in COVID-19 patients. Special attention is given to antifungal therapeutics, the role of steroids and glycemic

control, preventive measures, and the implications of co-treatment with antiviral and antimicrobial agents. Understanding the interplay between COVID-19 and fungal coinfections is critical for timely diagnosis, effective intervention, and improved patient outcomes.

2. LITERATURE REVIEW

2.1 Introduction to Fungal Coinfections in COVID-19

Fungal coinfections in COVID-19 patients have become an alarming secondary complication, especially in those with comorbidities like diabetes mellitus or immunosuppressive conditions. COVID-19-associated mucormycosis (CAM), pulmonary aspergillosis, and *Candida auris* outbreaks have surged significantly, with increased morbidity and mortality rates [7], [8], [10].

2.2 Mucormycosis: Epidemiology and Diagnostic Strategies

Mucormycosis, or "black fungus," has been observed with higher prevalence in India during the second wave of COVID-19. It primarily affects patients with uncontrolled diabetes who received corticosteroids as part of COVID-19 management [10], [11].

Multiple AI-based models have been developed to detect mucormycosis early using CT imaging and deep learning algorithms [2], [3], [4], [5]. Begum et al. [1] proposed phytochemical compounds from *Polygonatum odoratum* as novel antifungal agents targeting the 14-alpha-demethylase enzyme.

Annie Grace Vimala et al. [3] demonstrated an AI-based early warning system utilizing multimodal imaging to identify black fungus infection before critical progression. Similarly, Valarmathi et al. [4] developed a machine learning framework for mucormycosis prediction using enhanced learning principles.

2.3 Pulmonary Aspergillosis in COVID-19 Patients

COVID-19-associated pulmonary aspergillosis (CAPA) has emerged as a significant concern among ICU-admitted patients. Salmanton-García et al. [12] presented a systematic review highlighting CAPA's incidence, diagnostic complexity, and associated mortality. Despite the absence of classical risk factors, severely ill COVID-19 patients may develop invasive aspergillosis due to immune dysregulation and prolonged ventilation [10], [11].

2.4 *Candida auris* and Healthcare-Associated Outbreaks

The highly resistant fungal pathogen *Candida auris* has seen outbreaks in COVID-19 specialty care units, particularly in high-dependency and long-term care settings [13], [14]. Prestel et al. [14] reported its rapid spread during equipment re-use and inadequate sterilization practices. Allaw et al. [13] highlighted *C. auris* emergence in Lebanon during the pandemic, stressing the importance of improved infection control. Pilato et al. [17] performed molecular epidemiological investigations, underscoring *C. auris*'s ease of transmission during COVID-19 surges.

2.5 Antifungal Pharmacotherapy and Clinical Management

Amphotericin B remains the gold-standard therapy for mucormycosis, but its nephrotoxicity and limited availability pose challenges [10]. Alternative agents like posaconazole and isavuconazole are used, particularly when surgical debridement is not feasible [11].

Advanced neural network models, such as CNN-XGBoost hybrids, have been developed to automate mucormycosis detection and support clinical decision-making [6]. Erku et al. [28] emphasized pharmacists' critical role in combating misinformation and ensuring the rational use of antifungals.

Mussini et al. [23] and Brissot et al. [24] provided clinical guidelines on managing severe fungal complications in COVID-19 patients, focusing on antifungal stewardship and the integration of clinical imaging.

2.6 Risk Factors: Diabetes, Steroid Use, and Immunosuppression

The interplay of hyperglycemia, corticosteroids, and immunosuppressive therapies has been recognized as a major risk factor for fungal infections. John et al. [10] and Moorthy et al. [11] termed this synergy the "Unholy Trinity" of COVID-19-associated mucormycosis. Patients recovering from COVID-19 with high-dose steroids showed delayed onset of mucormycosis, particularly involving the orbit and cranial regions [8], [9]. Khurana et al. [21] showed the increasing burden of fungal and bacterial co-infections during the pandemic.

2.7 Diagnostic and Surveillance Challenges

CAPA and CAM are often misdiagnosed due to overlapping radiological and clinical presentations with COVID-19 pneumonia. Basso et al. [16] reported histoplasmosis in immunocompromised COVID-19 patients, emphasizing the need for molecular diagnostics. Several studies also call attention to limited diagnostics in LMICs [25], [26], while advanced countries have used wastewater surveillance to predict fungal outbreaks [27].

2.8 Vaccine and Prevention Strategies

Though fungal vaccines are still under development, ongoing COVID-19 vaccination has indirectly reduced hospitalization and secondary infections [19], [20]. Sim et al. [30], [32] discussed the economic aspects of immunization strategies relevant to pandemic preparedness. Torner [38] emphasized that the diversion of resources during COVID-19 affected routine immunization programs, potentially increasing fungal infection susceptibility.

2.9 Environmental and Public Health Considerations

Wang et al. [36] and Gholipour et al. [37] identified that wastewater aerosols may pose a risk for fungal transmission in dense environments. Chi et al. [42] highlighted the need for a holistic public health response to manage collateral fungal infections in COVID-19 patients.

2.10.Medicinal Plants for Hepatocellular Carcinoma Therapy

Farheen et al. [37] investigated medicinal plants as therapeutic candidates for hepatocellular carcinoma. Their mini-review pointed out the hepatoprotective properties of phytochemicals and their potential to provide affordable, accessible alternatives to conventional cancer treatments.

2.11. Bioactive Compounds Interacting with Mosquito Proteins

Geetha et al. [38] used computational methods to evaluate natural bioactive compounds and their interactions with mosquito proteins. This research provides insights for novel insecticide design and biocontrol measures, advancing eco-friendly mosquito management strategies.

2.12. Biofuel Production from Fruit Waste

Devasena et al. [39] highlighted sustainable biofuel production from fruit waste, offering a waste-to-energy approach. Their work underscored the dual benefit of reducing organic waste accumulation and providing renewable energy alternatives to fossil fuels.

2.13. Airborne Microbial Load in Clinical Environments

Krishanan et al. [40] quantified airborne microbial loads in clinical and adjacent environments. Their study demonstrated the importance of microbial monitoring for infection control and prevention, contributing to improved healthcare facility management.

2.14. Wastewater Irrigation and Plant Growth

Krishanan et al. [41] studied the effect of aquarium wastewater irrigation on mustard and green gram plants. Results indicated enhanced growth responses, suggesting the feasibility of using treated wastewater in agriculture as a resource recovery and sustainability measure.

3. MUCORMYCOSIS (MUM)

3.1 Etiology and Transmission

Mucormycosis (MUM), colloquially referred to as "black fungus," is caused by fungi belonging to the order Mucorales, primarily the genera Rhizopus, Mucor, and Lichtheimia. These fungi are ubiquitous in nature, particularly in soil, decaying organic matter, and animal excreta. Transmission primarily occurs through the inhalation of fungal spores, though direct inoculation through wounds or ingestion can also lead to infection [8], [10].

3.2 Clinical Manifestations

Clinical symptoms depend on the infection site. Rhinocerebral mucormycosis, the most common form in COVID-19 patients, manifests as nasal congestion, facial pain, periorbital swelling, and black necrotic eschar. Pulmonary involvement presents as cough, chest pain, dyspnea, and fever. Disseminated infection may involve the brain, kidneys, and gastrointestinal tract, often leading to high mortality [9], [10].

3.3 Types of MUM

Table 1. Types of Mum

Type	Primary Site of Infection	Most Affected Group	Clinical Notes
Rhinocerebral	Sinuses and brain	Uncontrolled diabetics, especially with ketoacidosis [11]	Common in COVID-19 patients, may lead to vision loss
Pulmonary	Lungs	Cancer patients, transplant recipients [12]	Mimics pneumonia, difficult to differentiate radiologically
Gastrointestinal	Stomach and intestines	Premature neonates, immunocompromised children [13]	Rare; leads to abdominal pain, bleeding
Cutaneous	Skin (trauma/surgical sites)	Patients with burns, wounds, or post-surgery [14]	Presents with necrotic ulcers and skin lesions
Disseminated	Multiple organs (via bloodstream)	Severely immunosuppressed individuals [15]	Rapid progression; high mortality

3.4 Risk Factors

Risk factors include diabetes mellitus (especially with ketoacidosis), prolonged corticosteroid use, neutropenia, immunosuppressive therapy, malignancies, and organ transplantation [10], [11]. COVID-19 exacerbates these risks due to immune dysregulation, widespread steroid use, and elevated blood glucose levels.

3.5 Diagnosis and Imaging

Diagnosis involves clinical examination, nasal endoscopy, imaging (CT/MRI), and histopathological confirmation. Radiological signs include sinus opacification, bone erosion, and orbital extension. PCR and fungal culture from tissue biopsies are definitive [8], [11].

3.6 Management and Treatment

Treatment involves rapid antifungal therapy (liposomal amphotericin B, posaconazole), surgical debridement, and management of underlying conditions like diabetes. Early initiation of therapy significantly improves survival [10].

Table 2. Treatment Methodology and Description

Treatment Modality	Description
Antifungal Therapy	Liposomal amphotericin B, posaconazole, isavuconazole
Surgical Debridement	Removal of necrotic tissues to prevent spread
Glycemic Control	Strict blood sugar management, especially in diabetic patients
Reduce Immunosuppression	Limiting steroid and immunomodulatory drug use
Early Diagnosis	Essential to reduce mortality and prevent complications

3.7 Case Studies

Dr. Nair in Mumbai documented several severe cases during India's second COVID-19 wave, many requiring orbital exenteration due to delayed diagnosis. Similar trends were reported in Delhi, Pune, and Bangalore, highlighting the aggressive progression of MUM in COVID-19-recovered patients [8], [9].

4. PATHOPHYSIOLOGICAL MECHANISM

COVID-19 leads to immune dysregulation characterized by lymphopenia, cytokine storm, and T-cell exhaustion. These factors reduce the body's innate ability to recognize and destroy fungal pathogens. Additionally, SARS-CoV-2 infection damages epithelial barriers in the respiratory tract, providing an entry point for invasive fungi.

Corticosteroids, while mitigating the inflammatory response in severe COVID-19, suppress neutrophil chemotaxis and macrophage activation. This inhibition compromises the immune response, particularly in the alveolar spaces where fungal spores can germinate. Long-term or high-dose steroid therapy also contributes to lymphocyte depletion, further impairing host defenses.

In diabetic patients, hyperglycemia creates an ideal environment for fungal growth. Acidosis, particularly diabetic ketoacidosis (DKA), increases available serum iron levels, which promotes the growth of Mucorales. Elevated glucose levels impair neutrophil function and reduce the efficacy of oxidative bursts needed to eliminate fungal pathogens.

Other contributing factors include prolonged hospitalization, use of broad-spectrum antibiotics that disrupt microbiota balance, and invasive procedures such as mechanical ventilation or central venous catheters. All these elements collectively lead to a highly susceptible immunological state, allowing opportunistic fungi like *Mucor*, *Aspergillus*, and *Candida auris* to invade and disseminate rapidly.

The convergence of these risk factors—viral-induced immunosuppression, pharmacological immunomodulation, and metabolic dysregulation—represents a "perfect storm" for the onset of life-threatening fungal infections in COVID-19 patients [10], [11].

5. OTHER FUNGAL INFECTIONS

5.1 COVID-19-Associated Pulmonary Aspergillosis (CAPA)

CAPA is increasingly reported in ICU patients. It presents with respiratory distress, hemoptysis, and persistent fever. Diagnosis involves galactomannan testing and fungal culture from bronchoalveolar lavage. Treatment includes voriconazole or isavuconazole [12].

5.2 Candida auris Outbreaks

Candida auris is a multidrug-resistant yeast associated with nosocomial outbreaks. Its rise during COVID-19 is linked to ICU stays, indwelling devices, and compromised infection control. Echinocandins are first-line treatments [13], [14].

5.3 Fungal Pneumonia Resembling COVID-19

Fungal pneumonias like histoplasmosis and blastomycosis may mimic COVID-19 radiologically and clinically. In COVID-negative but symptomatic cases, fungal testing is essential. Antifungal therapy varies depending on etiology [16].

Risk Factor	Prevention Strategy	Rationale
Steroid Use	Use only when needed	Avoids immunosuppression
Humidifier Hygiene	Use sterile water	Prevents contamination
Diabetes	Monitor blood sugar	Reduces fungal risk
ICU Equipment	Strict sterilization	Minimizes cross-infection

Oxygen Therapy	Use clean, filtered devices	Prevents fungal exposure

Table 3. Prevention & Management

5. RESULTS

The review revealed that fungal coinfections such as mucormycosis, aspergillosis, and Candida auris significantly affected hospitalized COVID-19 patients, particularly those in intensive care units and on corticosteroid therapy. Mucormycosis was most prevalent in India, often linked to diabetes and steroid overuse, while aspergillosis occurred rapidly after intubation and Candida auris posed a serious threat due to multidrug resistance. Mortality rates ranged from 30% to 70%, with delayed diagnosis contributing to worse outcomes. Antifungal resistance, especially in Candida auris and azole-resistant Aspergillus strains, remains a major concern, emphasizing the need for early detection and targeted treatment. Mucormycosis was most often associated with uncontrolled diabetes and corticosteroid therapy. Rhino-orbital-cerebral mucormycosis (ROCM) was the most reported form. Aspergillosis showed a rapid onset after intubation and was linked to immunosuppressed and elderly patients. Candida auris infections showed high rates of bloodstream infections (candidemia) and colonization in ICU equipment and surfaces.

DISCUSSION

Fungal coinfections such as MUM and CAPA show a higher mortality in COVID-19 patients (30–80%) compared to the general population. In India, uncontrolled diabetes and high steroid usage have worsened outcomes. Western countries report lower MUM incidence but face CAPA and *C. auris* threats due to prolonged ventilation and ICU stays [10], [12], [13]. Diagnosis is complicated by overlapping symptoms and delayed fungal identification. Additionally, the lack of awareness among healthcare professionals, limited access to diagnostic tools, and misdiagnosis with bacterial or viral pneumonia further delay treatment initiation. There is also a disparity in healthcare infrastructure between developed and developing nations, which impacts the timely management of fungal infections. From a pharmacological standpoint, managing these fungal infections is complex due to drug interactions, toxicity profiles, and rising antifungal resistance. Liposomal amphotericin B, although effective, is expensive and not always available in rural settings. Hence, a combined approach involving prompt diagnosis, aggressive antifungal treatment, and supportive care is vital. Global data sharing, standardized guidelines, and research on antifungal drug development are crucial for better preparedness in future pandemics. Collaborative efforts involving clinicians, microbiologists, pharmacists, and public health authorities are necessary to improve patient outcomes.

CONCLUSION

Fungal coinfections significantly complicate COVID-19 management, particularly in immunocompromised and diabetic individuals. These infections contribute to increased ICU stays, delayed recovery, and higher fatality rates. The convergence of risk factors—such as hyperglycemia, immunosuppression from steroids, and prolonged hospitalization—creates an ideal environment for fungal pathogens.

A multidisciplinary approach, integrating early diagnostic protocols, timely antifungal therapy, and stringent infection control practices, is essential. Public awareness campaigns should educate both patients and healthcare workers on early signs of fungal infections.

Furthermore, there is a pressing need for affordable and accessible antifungal medications in low- and middle-income countries. Investment in research for novel antifungal agents and rapid diagnostic kits is crucial to reduce the global burden of these infections.

In conclusion, a proactive and collaborative framework is critical to combat fungal coinfections in the COVID-19 era and beyond, ensuring better patient safety, clinical outcomes, and healthcare resilience.

REFERENCES

- Begum, Ameen, S. S. Nagar, R. S. Upendra and R. Karthik, "Discovery of Novel Antifungal Agents from Polygonatum odoratum Targeting 14-Alpha Demethylase Enzyme for the Treatment of Black Fungus (Mucormycosis)," 2024 International Conference on Intelligent Systems and Advanced Applications (ICISAA), Pune, India, 2024, pp. 1-5, doi: 10.1109/ICISAA62385.2024.10829343.
- N. Shivaanivarsha, P. Kavipriya and M. Shyamkumar, "An Efficient Fully Automated Detection of Mucormycosis Using Three-Dimensional Deep Learning on Computer Tomography Studies," 2023 International Conference on Recent Advances in Electrical, Electronics, Ubiquitous Communication, and Computational Intelligence (RAEEUCCI), Chennai, India, 2023, pp. 1-6, doi: 10.1109/RAEEUCCI57140.2023.10134269.
- G. S. Annie Grace Vimala, R. Kesavan, E. Manigandan, S. P. Latha, B. V. Kumar and S. Padmakala, "Black Fungus Infection Detection using AI-based Early Warning System for Patients through Multi-Modal Medical Imaging," 2023 2nd International Conference on Automation, Computing and Renewable Systems (ICACRS), Pudukkottai, India, 2023, pp. 1783-1789, doi: 10.1109/ICACRS58579.2023.10404938.
- P. Valarmathi, P. Vasudevan, Y. Suganya and T. JahirHussain, "A Robust Development to Predict Black Fungus Disease with Enhanced Learning Principles," 2024 Ninth International Conference on Science Technology Engineering and Mathematics (ICONSTEM), Chennai, India, 2024, pp. 1-6, doi: 10.1109/ICONSTEM60960.2024.10568773.
- P. S. Charan and G. Ramkumar, "Mucormycosis Detection using Hybrid Convolutional Neural Network with Support Vector Machine and Compare the performance with Support Vector Machine," 2023 International Conference on Artificial Intelligence and Knowledge Discovery in Concurrent Engineering (ICECONF), Chennai, India, 2023, pp. 1-8, doi: 10.1109/ICECONF57129.2023.10083770.
- P. V. Sai Charan and G. Ramkumar, "Modified Convolutional Neural Network Architecture with XGBoost for Mucormycosis Detection and compare performance with XGBoost," 2023 International Conference on Artificial Intelligence and Knowledge Discovery in Concurrent Engineering (ICECONF), Chennai, India, 2023, pp. 1-8, doi: 10.1109/ICECONF57129.2023.10084019.
- Aranjani JM et al., COVID-19-associated mucormycosis: Evidence-based critical review…, PLoS Negl Trop Dis, 2021, doi:10.1371/journal.pntd.0009921.
- D. Garg et al., "Coronavirus disease (Covid-19) associated mucormycosis (CAM): Case report and systematic review of literature," Mycopathologia, vol. 186, no. 1, pp. 1–10, 2021.
- M. Sen et al., "Mucor in a viral land: A tale of two pathogens," Indian J. Ophthalmol., vol. 69, no. 2, pp. 244–245, 2021.
- T. M. John, C. N. Jacob, and D. P. Kontoyiannis, "When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis," J. Fungi, vol. 7, no. 4, p. 298, 2021.
- A. Moorthy et al., "SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids—An Unholy Trinity in Invasive Fungal Infections," J. Maxillofac. Oral Surg., 2021.
- S. Salmanton-García et al., "COVID-19–associated pulmonary aspergillosis, March–August 2020," Emerg. Infect. Dis., vol. 27, no. 4, pp. 1077–1080, 2021.
- F. Allaw et al., "First Candida auris outbreak during a COVID-19 pandemic in a tertiary-care center in Lebanon," Pathogens, vol. 10, no. 2, p. 157, 2021.

- A. Prestel et al., "Candida auris outbreak in a COVID-19 specialty care unit—Florida," MMWR, vol. 70, no. 2, pp. 56–57, 2021.
- Kanwar et al., "A fatal case of Rhizopus azygosporus pneumonia following COVID-19," J. Fungi, vol. 7, no. 3, p. 174, 2021.
- R. P. Basso et al., "COVID-19-associated histoplasmosis in an AIDS patient," Mycopathologia, vol. 186, no. 1, pp. 109–112, 2021.
- R. Pilato et al., "Molecular epidemiological investigation of a nosocomial cluster of C. auris," J. Fungi, vol. 7, no. 2, p. 140, 2021.
- Kumar et al., "SARS-CoV-2 antibodies in healthcare workers in a large university hospital, Kerala, India," Clin. Microbiol. Infect., vol. 27, no. 3, pp. 481–483, 2021.
- Chohan, U. W. (2020). After the Coronavirus Vaccine's Discovery: Concerns Regarding a COVID-19 Vaccination's Distribution.
- Toh, Z. Q., Russell, F. M., Garland, S. M., Mulholland, E. K., Patton, G., &Licciardi, P. V. (2021). Human papillomavirus vaccination after COVID-19. JNCI Cancer Spectrum, 5(2), pkab011.
- M. Khurana et al., "Profile of co-infections and secondary infections in COVID-19 patients," Indian J. Med. Microbiol., vol. 39, no. 2, pp. 147–153, 2021.
- J. T. Mohindra et al., "COVID-19 infection in a HIV positive healthcare worker," VirusDisease, pp. 1–5, 2021.
- F. Mussini et al., "Therapeutic strategies for severe COVID-19," Clin. Microbiol. Infect., vol. 27, no. 3, pp. 389–395, 2021.
- E. Brissot et al., "Management of patients with acute leukemia during the COVID-19 outbreak," Bone Marrow Transplant., vol. 56, no. 3, pp. 532–535, 2021.
- M. Noushad and I. S. Al-Saqqaf, "COVID-19 case fatality rates in fragile nations," Clin. Microbiol. Infect., vol. 27, no. 4, pp. 509–510, 2021.
- W. H. Chen et al., "A stable yeast-expressed SARS-CoV-2 vaccine candidate," Biochim. Biophys. Acta Gen. Subj., vol. 1865, no. 6, p. 129893, 2021.
- F. Hassard et al., "Innovation in wastewater tracking for COVID-19," Lancet Microbe, vol. 2, no. 1, pp. e4–e5, 2021.
- A. Erku et al., "Pharmacists' role in deterring medication misinformation," Res. Soc. Adm. Pharm., vol. 17, no. 1, pp. 1954–1963, 2021.
- S. Soin et al., "Tocilizumab plus standard care for COVID-19 cytokine release syndrome," Lancet Respir. Med., vol. 9, no. 5, pp. 511–521, 2021.
- M. Sim et al., "Costs of immunization programs in LMICs from 2011 to 2030," Value Health, vol. 24, no. 1, pp. 70–77, 2021.
- K. M. Thompson and D. A. Kalkowska, "Future use and value of poliovirus vaccines," Risk Anal., vol. 41, no. 2, pp. 349–363, 2021.
- S. Y. Sim et al., "Costs of immunization programs for 10 vaccines," Value Health, vol. 24, no. 1, pp. 70–77, 2021.
- U. W. Chohan, "After the Coronavirus Vaccine's Discovery," J. Vaccine Policy, 2020.
- Q. Toh et al., "HPV vaccination after COVID-19," JNCI Cancer Spectrum, vol. 5, no. 2, p. pkab011, 2021.
- R. C. Das, "Management of COVID-19 Through Strategic Roles of Governments," in Management Strategies to Survive in a Competitive Environment, pp. 275–284.
- X. Wang, K. K. Sahu, and J. Cerny, "Potential role of complement inhibition in COVID-19," J. Thromb. Thrombolysis, vol. 51, no. 3, pp. 657–662, 2021.
- S. Gholipour et al., "COVID-19 infection risk from aerosols at wastewater plants," Chemosphere, vol. 273, p. 129701, 2021.
- N. Torner, "Collateral effects of COVID-19 on global immunization," Vacunas (English Edition), vol. 21, no. 2, pp. 73–75, 2020.
- R. Adegbola, "Childhood pneumonia and strategic interests of Gates Foundation," Clin. Infect. Dis., vol. 54, suppl. 2, pp. S89–S92, 2012.
- Noushad, M., & Al-Saqqaf, I. S. (2021). COVID-19 case fatality rates can be highly misleading in resource-poor and fragile nations: the case of Yemen. Clinical Microbiology and Infection, 27(4), 509-510.
- Wang, X., Sahu, K. K., &Cerny, J. (2021). Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. Journal of thrombosis and thrombolysis, 51(3), 657-662.
- Chi, Y. L., Regan, L., Nemzoff, C., Krubiner, C., Anwar, Y., & Walker, D. (2020). Beyond COVID-19: A Whole of Health Look at Impacts During the Pandemic Response.
- N. Farheen, S. E. Sangeetha, B. Devasena, L. Ashwini, and N. B. Geetha, "Exploring medicinal plants for hepatocellular carcinoma therapy: A mini review," *TBS Journal*, vol. 20, no. 2, pp. 590–592, 2025, doi: 10.63001/tbs.2025.v20.i02.S2.pp590-592.
- N. B. Geetha, S. E. Sangeetha, B. Devasena, L. Ashwini, N. Farheen, and J. Mahalakshmi, "Computational insights into natural bioactive compounds interacting with mosquito proteins," *TBS Journal*, vol. 20, no. 2, pp. 593–595, 2025, doi: 10.63001/tbs.2025.v20.i02.S2.pp593-595.
- B. Devasena, S. K. Kiran, W. Anitha, B. Balaji, and J. Mahalakshmi, "Sustainable biofuel production from fruit waste: A waste-to-energy approach," *TBS Journal*, vol. 20, no. 2, pp. 606–609, 2025, doi: 10.63001/tbs.2025.v20.i02.S2.pp606-609.
- V. Krishanan, S. K. Kiran, K. Karthick, A. Sindhuja, and J. Mahalakshmi, "Quantitative assessment of airborne microbial load in clinical and adjacent environments," *TBS Journal*, vol. 20, no. 2, pp. 610–613, 2025, doi: 10.63001/tbs.2025.v20.i02.S2.pp610-613.
- V. Krishanan, B. Devasena, N. Farheen, S. Shobana, and C. Geetha, "Growth response of mustard and green gram plants to aquarium wastewater irrigation," *TBS Journal*, vol. 20, no. 2, pp. 614–617, 2025, doi: 10.63001/tbs.2025.v20.i02.S2.pp614-617.